Jonathan Olsen, DO
Allergy & Immunology · Draper, UTNPI 1518287846
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,550 of the $59,776 with a category attached, or 72.9%. GSK accounts for 91.8% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $40,844 and has fallen 99.6% since, to $158 in 2025. Among allergy & immunology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $254.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$55K
- Pharming Healthcare, Inc.$951
- AstraZeneca$805
- Sanofi$632
- Regeneron Healthcare Solutions, Inc.$320
- Amgen$248
- plus $2K from 25 others
What the payments were for
- Consulting fees$5,0338%
- Speaking & faculty fees$43,55073%
- Travel & lodging$5,77710%
- Food & beverage$5,3519%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 58 | $54,883 |
| Pharming Healthcare, Inc. | 9 | $951 |
| AstraZeneca | 33 | $805 |
| Sanofi | 33 | $632 |
| Regeneron Healthcare Solutions, Inc. | 11 | $320 |
| Amgen | 12 | $248 |
| Kaleo, Inc. | 8 | $198 |
| Novartis | 6 | $195 |
| Boston Scientific | 1 | $158 |
| ADMA Biomanufacturing LLC | 3 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $157 |
| Biocryst US Sales Co., LLC | 6 | $131 |
| Teva Pharmaceuticals USA, Inc. | 8 | $125 |
| Genentech USA, Inc. | 6 | $114 |
| CSL Behring | 4 | $111 |
| Grifols USA, LLC | 5 | $101 |
| Blueprint Medicines Corporation | 1 | $75 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Sunovion Pharmaceuticals Inc. | 6 | $64 |
| Pfizer | 3 | $54 |
| AbbVie | 2 | $37 |
| Bio Products Laboratory USA, Inc. | 2 | $31 |
| Pulmonx Corporation | 1 | $25 |
| Novo Nordisk | 1 | $22 |
| LEO Pharma Inc. | 1 | $21 |
| Optinose US, Inc. | 1 | $19 |
| Strongbridge US Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$48,421
- RUCONEST$816
- General - Interventional Oncology$158
- TEZSPIRE$146
- DUPIXENT$109
How this compares
$59,776 in reported general payments places this provider in the 95th percentile of 30 allergy & immunology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 22 | $123,149 |
| TezspireTezepelumab-Ekko | 13 | $57,553 |
| XolairOmalizumab | 18 | $48,882 |
| IcatibantIcatibant Acetate | 11 | $36,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $23,203 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,868 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $4,988 |
| Epinephrine | 24 | $4,673 |
| Azelastine Hcl | 54 | $1,873 |
| Ipratropium Bromide | 67 | $1,198 |
| Famotidine | 33 | $1,002 |
| Montelukast Sodium | 94 | $630 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $617 |
| Fluticasone Propionate | 15 | $375 |
| Azithromycin | 27 | $232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire | $805 | $57,55313 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $54,883 | $32,07137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 allergy & immunology providers in Utah.
Other allergy & immunology in Draper
- Duane HarrisDraper$1K
- Andrew SmithSandy$649K
- Jaron AbbottProvo$22K
- Tara SarinMurray$20K
- Richard HendershotPark City$16K
- Loida Viera HutchinsMurray$8K
- Stephen BodenBountiful$7K
- Alexander NicholsonWest Jordan$7K
- Joshua BurkhardtSalem$6K
- Evan MathesonProvo$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.